REGN – regeneron pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its "neutral" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $925.00 price target on the stock.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Is Weakness In Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects? [Yahoo! Finance]
UPDATE 1-Regeneron misses profit estimates on weaker Eylea and Dupixent sales [Yahoo! Finance]
Regeneron Reports First Quarter 2024 Financial and Operating Results [Yahoo! Finance]
Form 4 REGENERON PHARMACEUTICAL For: May 01 Filed by: McCourt Marion
Form 4 REGENERON PHARMACEUTICAL For: May 01 Filed by: RYAN ARTHUR F
Form 10-Q REGENERON PHARMACEUTICAL For: Mar 31
Form 8-K REGENERON PHARMACEUTICAL For: May 02
Form 144 REGENERON PHARMACEUTICAL Filed by: RYAN ARTHUR F
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.